Home・Aandelen Lijst・Insmed

Insmed

Gesloten

SectorGezondheidszorg

98.72 0.46

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

96.22

Max

99.38

Belangrijke statistieken
By Trading Economics
Inkomsten	165M -164M
Verkoop	42M 306M
EPS	-0.76
Winstmarge	-53.458
Werknemers	1,664
EBITDA	164M -136M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+100.98% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7.5B 23B
Vorige openingsprijs	98.26
Vorige sluitingsprijs	98.72

Nieuwssentiment

By Acuity

43%

57%

135 / 340 Rangschikking in Healthcare

Insmed Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 jul 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 jul 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 jul 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 jul 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 jul 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 jul 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 jul 2026, 17:41 UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 jul 2026, 19:16 UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Peer Vergelijking

Prijswijziging

Insmed Prognose

Koersdoel

By TipRanks

100.98% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 198.17 USD 100.98%

Hoogste 243 USD

Laagste 160 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor Insmed - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan Insmed - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

135 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.